ACTC to Enroll Patients With Better Vision in Stem Cell Trials

February 5, 2013

In late January, Advanced Cell Technology, Inc. (OTCBB: ACTC) announced that it is amending the patient treatment protocol to enroll patients with better vision for the remainder of its Phase I clinical stem cell trials for Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) currently being conducted in the U.S. and Europe. As such, patients with a visual acuity of 20/100 will be eligible for enrollment in the remainder of the trials (whereas previously, only patients with a visual acuity of 20/400 were eligible to participate).

By treating patients at an earlier stage of SMD and dry AMD disease, ACTC believes that treatment can have a more significant positive impact on patients’ photoreceptor rescue and visual function.

Click here to read the full press release.




Jump down to form below to submit your own comments

Comments are closed.